Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

0.2109 -0.0291 (-12.12%)
Streaming Delayed Price Updated: 1:32 PM EDT, May 9, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Cns Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Study Finds DNA Loops in Brain Tumors in Kids Amplify Relapse Risk
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Release Interim Data by Year End for Lead Treatment Candidate Berubicin
Via Investor Brand Network
Topics Death
Exposures Death
CNS Pharmaceuticals To Release Interim Data By The End Of The Year For Potential Glioblastoma Drug Candidate
Via ACCESSWIRE
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q3 2023 Financial Results, Update on Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference
Via ACCESSWIRE
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
Via ACCESSWIRE
Brain Cancer Reemergence Could Soon Be Detected Using a Finger-Prick Test
Via Investor Brand Network
Stanford Study Finds Lung Cancer Cells Hide, Thrive in the Brain
Via Investor Brand Network
Spanish Clinical Trial to Explore Marijuana as Glioblastoma Treatment
Via Investor Brand Network
Topics Cannabis
Exposures Cannabis
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Advancing Drive Toward Potential New GBM Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Announces Participation at Upcoming Virtual Investor Ask the CEO Conference
Via Investor Brand Network
Sonobiopsy Promises Easier Way to Diagnose Brain Tumors
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Innovative Glioblastoma Treatment ‘Could Offer Hope’
Via Investor Brand Network
Exposures Product Safety
Glioblastoma Is the Most Aggressive Type of Brain Cancer, With No Cure - CNS Pharmaceuticals’ Innovative Approach To Treatment Could Offer Hope
Via ACCESSWIRE
Researchers Look for Novel Immunomodulating Targets with Potential to Transform Glioblastoma Treatment
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Rapid Pace of Enrollment in Potentially Pivotal Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals' (NASDAQ:CNSP) Ongoing Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme (GBM) Continues Rapid Pace of Enrollment with 229 Patients Enrolled to Date
Via ACCESSWIRE
First Time Ever: Researchers Eliminate Brain Cancer Using Quantum Therapy
Via Investor Brand Network
Novel Type of Immunotherapy Exhibits Efficacy Against Brain Tumors in Mouse Models
Via Investor Brand Network
Surgical Robot Prototype Could Ease Pediatric Brain Cancer Surgery
Via Investor Brand Network
Trial Enrollment Growth Supports Plans of CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) to Complete Enrollment for Important Brain Cancer Drug Study
Via Investor Brand Network
Nottingham University Researchers Find Way to Make Brain Cancer Cells Self-Destruct
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Optimistic Berubicin May Provide Much-Needed Benefit for GBM Patients
Via Investor Brand Network
Microdevices to Enable Simultaneous Multiple Studies on Potential Brain Cancer Treatments
Via Investor Brand Network
Study Shares Insights on Why Brain Tumors Are Unresponsive to Immunotherapy
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Looking Forward to Upcoming Interim Results for Potentially Pivotal GBM Study
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces 200-Patient Enrollment Milestone in Potentially Pivotal Berubicin Study
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) Reaches Milestone with Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (GBM)
Via ACCESSWIRE
Policies Encouraging High-Volume Facilities Disadvantage Oncology Patients in Rural Areas
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at Upcoming H.C. Wainwright Global Investment Conference
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.